Last reviewed · How we verify
NCT05018065
Sexual Functions and Covid-19
NA trial testing Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI) in Covid19 in 101 participants. Completed in 30 December 2020.
1 December 2020
Quick facts
| Lead sponsor | Gaziosmanpasa Research and Education Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | other |
| Enrollment | 101 |
| Start date | 1 May 2020 |
| Primary completion | 1 December 2020 |
| Estimated completion | 30 December 2020 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)
Conditions studied
- Covid19 — all drugs for Covid19 →
- Sexual Behavior — all drugs for Sexual Behavior →
Sponsor
Gaziosmanpasa Research and Education Hospital
Who can join
Adults 30 to 45, female only, with Covid19 or Sexual Behavior. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sexual health is one the important components of life quality. The aim of this study is to compare sexual dysfunction of women who survived Covid-19 and who didn't undergo Covid-19.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05018065
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Gaziosmanpasa Research and Education Hospital trials
Trials by the same sponsor.
- NCT07459400 — The Effect of Peloidotherapy in Young Adults Undergoing Physical Therapy Scoliosis Specific Exercises (PSSE) · not yet recruiting
- NCT07366814 — Pipelle Versus Karman Endometrial Biopsy Under Standardized Paracervical Block · NA · completed
- NCT07372430 — Proximal Versus Distal Superior Cluneal Nerve Block in Entrapment Neuropathy · recruiting
- NCT07459413 — Oral vs. Intravenous Hydration to Prevent Contrast-Associated Acute Kidney Injury in the ED · NA · recruiting
- NCT07272213 — Thyroid-Stimulating Hormone Levels in Pregnancy and Their Association With Depression, Anxiety, and Sexual Function · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05018065 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gaziosmanpasa Research and Education Hospital
- Last refreshed: 27 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05018065.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing